Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...
Tourmaline Bio (TRML) Gets a Buy from Wedbush
In a report released today, Laura Chico from Wedbush maintained a Buy rating on Tourmaline Bio (TRML – Research Report), with a price target of ...
TD Cowen Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s ...
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...
pharmaphorum20h
Competition for Neurocrine as Gocovri picks up new Parkinson's indication
Neurocrine had to delay the launch of Ongentys until September after an FDA approval in April because of disruption caused by COVID-19. The company in-licensed Ongentys from Portugal’s BIAL ...